

Biomarker-assessed passive smoking in relation to cause-specific mortality: pooled data from 12 prospective cohort studies comprising 36 584 individuals

Running head: Salivary cotinine and mortality

Elisabeth Kvaavik,^a PhD (E-mail: elisabeth.kvaavik@fhi.no; ORCID: 0000-0003-4570-0265)
Senior researcher

Aage Tverdal,^b PhD (E-mail: aage.tverdal@fhi.no; ORCID: 0000-0002-2909-5678)
Senior researcher

G. David Batty,^c PhD, DSc (E-mail: david.batty@ucl.ac.uk; ORCID: 0000-0003-1822-5753)
Professor of Epidemiology

^aDepartment of Alcohol, Tobacco and Drugs, Norwegian Institute of Public Health, Oslo, Norway

^bCentre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway

^cDepartment of Epidemiology and Public Health, University College London, London, UK

Correspondence: Elisabeth Kvaavik, Norwegian Institute of Public Health, Department of Alcohol, Tobacco and Drugs, PO Box 222, Skøyen, N-0213 Oslo, Norway. E-mail: elisabeth.kvaavik@fhi.no

Manuscript statistics: Word count: 1963 (abstract and references excluded), tables: 2, coloured figures: 1, figures: 1, supplementary tables: 1, references: 39.

Key words: Passive Smoking, Mortality, Measurement.

Abstract

Aims: While investigators have typically quantified the health risk of passive (second hand) smoking by utilising self-reported data, these are liable to measurement error. By pooling data across studies, we examined the prospective relation of a biochemical assessment of passive smoking, salivary cotinine, with mortality from a range of causes.

Methods: We combined data from twelve cohort studies from England and Scotland initiated between 1998 and 2008. A total of 36 584 men and women aged 16 to 85 years of age reported that they were non-smoking at baseline, provided baseline salivary cotinine, and consented to mortality record linkage.

Results: A mean of 8.1 years of mortality follow-up of 36 584 non-smokers (16 792 men and 19 792 women) gave rise to 2367 deaths (775 from cardiovascular disease, 780 from all cancers, and 289 from smoking-related cancers). After controlling for a range of covariates, a 10 ng/ml increase in salivary cotinine was related to an elevated risk of total (hazard ratios; 95% confidence interval: 1.46; 1.16 to 1.83), cardiovascular disease (1.41; 0.96 to 2.09), cancer (1.49; 1.00 to 2.22) and smoking-related cancer mortality (2.92; 1.77 to 4.83).

Conclusions: Assessed biomedically, passive smoking was a risk factor for a range of health outcomes known to be causally linked to active smoking.

Introduction

Although there have been substantial secular declines in smoking prevalence in adults in the western world in recent years, more than 7 million UK adults still engage in the habit¹ and there are estimated to be over one billion smokers worldwide.² Consequently, although perhaps overestimates owing to the implementation of smoking bans in bars and restaurants in the UK,³ in 2002, up to 13% of non-smokers reported being passively exposed to tobacco smoke in the home and 10% in the workplace.⁴

Globally each year more than one million individuals are thought to die from passive smoking, also known as second-hand smoking or environmental tobacco smoke.² Such estimates are based on the numerous studies that have explored the health consequences of passive smoking with the suggestion that it is linked to most diseases known to be caused by active smoking, including cardiovascular disease and selected cancers.⁵ In these studies, investigators have typically relied upon self-reported measures of passive smoking, raising concerns regarding reporting error. Further, some of the evidence is based on case-control studies⁶⁻⁹ raising methodological concerns regarding reporting bias and reverse causality. While more recent reports have utilised biomarkers of passive smoking in analyses of mortality or morbidity cohort data,¹⁰⁻¹² interpretation of these findings is hampered by the small size of most studies. Accordingly, we pooled data for non-smokers across 12 cohort studies to explore the relation of salivary cotinine, a widely used indicator of passive smoking,¹³ with the risk of cause-specific mortality.

Methods

The Scottish Health Survey (SHS)¹⁴ and the Health Survey for England (HSE)¹⁵ are independent, near-identical, cross-sectional, general population-based studies examining individuals living in households in each country. Described extensively elsewhere,¹⁶⁻¹⁸ in the present analyses study members were aged 16-85 years at recruitment and were subsequently linked to a national cause-of-

death registry. For the present analyses, we utilised only those surveys with salivary cotinine data (SHS 1998 and 2003; HSE 1997–2004, 2007, and 2008). Participants gave full consent and ethical approval was provided by the London Research Ethics Council.

Assessment of active and passive smoking

Data on self-reported smoking were collected using standard enquiries (current, former and never smokers). For the cotinine assessment, a dental roll saturated with participant saliva was later analysed using a gas chromatographic method (Hewlett Packard HP5890) with a lower limit of detection of 0.1 ng/ml (levels below 0.1 ng/ml are regarded as being undetectable¹⁹). In the 2008 HSE this methodology was changed to a liquid chromatography tandem mass spectrometry method¹⁹ but the two methods produce comparable results.^{20 21} Internal quality control is described elsewhere.²² Average coefficient of variation (CV) is 3.9 % in the range 1 to 1000 ng/ml.^{19 22} Salivary cotinine, a metabolite (and anagram) of nicotine, is shown to be a valid marker of tobacco smoke exposure in the previous 72 hours and to show sufficiently high specificity and sensitivity for the purposes of population-based research.^{13 23 24}

Assessment of confounders

Self-reported confounding factors were sex, age, survey, socio-economic status, longstanding illness, and alcohol consumption. Study member occupation was coded according to the Registrar General classification for social class,²⁵ a six-level indicator of socio-economic status in which a lower score indicates greater prestige. Respondents reported if they suffered from a longstanding illness and their level of alcohol consumption (consumption at least 5 occasions per week was denoted as high). Longstanding illness was defined as ‘long-standing illness, disability or infirmity’ and the time period referred to was ‘anything that has troubled you over a period of time, or that is likely to affect you over a period of time’, with the response alternatives: *No, Yes, Don't know*.

Ascertainment of cause of death

Cause of death was based on certification and coded according to the *International Classification of Diseases* (ICD, 10th revision).²⁶ We generated outcomes for mortality from all-causes, cardiovascular disease (ICD codes I01-I99), and all cancers combined (C00-D48). Based on existing evidence,^{27 28} we also denoted smoking-related cancers as C01-C16, C22, C25, C30.0, C31; C32, C34, C53, C64-C67, C68.0, C68.1, C68.8, C68.9 and C92. These cancers are shown to have an established relation with smoking, and consist of cancers in the lung, stomach, pancreas, bladder, upper aero-digestive, kidney, myeloid leukaemia, and liver.^{27 28}

Statistical analyses

Altogether, 142 150 men and women were surveyed in 12 studies. Of these, 61 740 provided a salivary cotinine and 57 284 gave consent to use their data. After omitting self-reported smokers (N=12 862), participants with a cotinine value at or above 15 ng/ml (self-reported non-smokers with salivary cotinine \geq 15.00 ng/ml were regarded as deceivers) (N=1 971),^{29 30} and those without complete covariate data (N=5 867), 36 584 study members (19 792 women) remained. This was our analytical sample.

Having ascertained that the proportional hazards assumption had not been violated, we used Cox proportional hazards regression models³¹ to estimate hazard ratios (HR) with 95% confidence intervals (95% CI) to summarize the relationship between salivary cotinine level and risk of death. In these analyses, calendar time (months) was the time scale, with censoring taking place on date of death or end of mortality surveillance (February 15, 2011 for Health survey for England and December 31, 2009 for the Scottish Health Survey) – whichever came first. As there was no effect modification of the cotinine–death relation by sex or age, we combined men, women, and all ages in the analyses and adjusted for sex and age in addition to other covariates. We included survey year as fixed effects in the models. We entered two sets of covariates into the models: sex and age

(comparator model); and sex, age, survey year, social class, frequency of alcohol use, and long-standing illness. The mkspline procedure in STATA produced multivariable-adjusted spline curves for any death and deaths from cardiovascular disease, total cancer, and smoking-related cancer. We carried out all analyses using Stata version 14.1.³²

Results

Age, sex, social status, self-reported illness and former smoking varied with cotinine level such that study members in the lowest cotinine tertile were older and there was a lower proportion of men, manual workers and former smokers relative to the higher tertiles (Table 1). Further, higher proportions of participants in the lowest tertile reported longstanding illness than in the other groups. There was no difference in the prevalence of high alcohol intake according to cotinine categories. Salivary cotinine levels varied with study years, with lower levels after the smoking ban was implemented in UK in 2006 (results not shown). Cotinine levels varied substantially across smoking categories, with self-reported active smokers having the highest cotinine levels, see figure 1.

Table 1. Baseline characteristics by salivary cotinine level in 36 584 non-smokers

	All (0-14.9)	Salivary cotinine (ng/ml) tertiles			P-value for difference across tertiles
		Low (0-0.1)	Middle (> 0.1-0.5)	High (> 0.5-14.9)	
N	36 584	13320	11471	11793	
<i>Mean</i>					
Age (years)		51.9	48.9	46.0	< 0.001
Cotinine (ng/ml)		0.03	0.32	2.01	< 0.001
<i>Percentages</i>					
Males		41.7	44.9	51.6	< 0.001
Manual social class		30.7	36.0	46.5	< 0.001
Longstanding illness		46.4	44.7	43.8	< 0.001
High alcohol intake		18.3	17.3	18.5	0.06
Formers smokers		30.9	31.2	34.0	< 0.001

The 36 584 non-smoking study participants were followed up for a mean of 8.1 years (range: 0.02 to 13.1 years) giving rise to 2367 deaths (775 deaths from cardiovascular disease, 780 from all cancers, and 289 from smoking-related cancers). In table 2 we show the relation of salivary cotinine with mortality risk. The highest level of cotinine was associated with elevated rates of death from all-causes (hazard ratio; 95% confident interval: 1.25; 1.14, 1.38) cardiovascular disease

(1.33; 1.13, 1.58), and all cancers combined (1.20; 1.01, 1.42), with the strongest effect apparent for smoking-related cancers (1.57; 1.19, 2.06). There was some attenuation of risk after adjustment for multiple cofounding factors, although statistical significance at conventional levels was retained in most analyses. Mortality by continuous cotinine showed a similar pattern with elevated risk of death from any cause, cardiovascular disease, all cancers, and smoking-related cancer. Additional analysis for total mortality adjusted for physical activity, blood pressure, mental health and self-assessed general health was carried out. However, these adjustments did not change the result.

Table 2. Hazard ratios (95% confidence interval) for the association between salivary cotinine and mortality in 36 584 non-smokers

	Salivary cotinine			p-value for trend	Continuous salivary cotinine Per 10 ng/ml increase
Salivary cotinine (ng/ml)	Tertile 1 (low)	Tertile 2	Tertile 3		
Range	0-0.1	> 0.1-0.5	> 0.5-14.9		
Mean	0.03	0.32	2.01		
Total mortality					
No. of deaths	814	701	850		
Age- and sex-adjusted	1 (Ref)	0.95 (0.86, 1.05)	1.25 (1.14, 1.38)	0.001	1.74 (1.40, 2.18)
Multiple-adjusted ^a	1	0.91 (0.83, 1.01)	1.18 (1.07, 1.30)	0.002	1.46 (1.16, 1.83)
Cardiovascular disease mortality					
No. of deaths	264	227	284		
Age- and sex-adjusted	1	0.97 (0.81, 1.16)	1.33 (1.13, 1.58)	0.001	1.78 (1.21, 2.61)
Multiple-adjusted ^a	1	0.91 (0.76, 1.09)	1.22 (1.03, 1.45)	0.025	1.41 (0.96, 2.09)
Cancer mortality					
No. of deaths	275	216	288		
Age- and sex-adjusted	1	0.85 (0.71, 1.01)	1.20 (1.01, 1.42)	0.036	1.73 (1.17, 2.55)
Multiple-adjusted ^a	1	0.83 (0.69, 0.99)	1.13 (0.95, 1.34)	0.175	1.49 (1.00, 2.22)
Smoking-related cancer mortality					
No. of deaths	90	75	124		
Age- and sex-adjusted	1	0.90 (0.66, 1.23)	1.57 (1.19, 2.06)	0.001	3.20 (1.95, 5.22)
Multiple-adjusted ^a	1	0.88 (0.64, 1.19)	1.43 (1.08, 1.89)	0.010	2.92(1.77, 4.83)

^aAdjusted for sex, age, survey, social class, longstanding illness and alcohol intake.

Figure 2 shows the spline curves for death from all-causes, cardiovascular disease, all cancers combined, and smoking-related cancers in which we illustrate thresholds of risk in relation to cotinine levels. The curves indicate that there is an increase in mortality from all causes, cancer and cardiovascular disease with increasing cotinine levels with a plateau at around 2 ng/ml such that no association seems to be present thereafter. For smoking-related cancer, this inflection is less apparent. .

Discussion

The main finding of the present analyses was that salivary cotinine, our biomarker of passive smoking, was associated with elevated rates of mortality from various causes, effects that was independent of selected confounding variables. The magnitude of these relationships was, as anticipated, lower than those apparent for active smoking (se Supplementary Table).

Comparison with published studies

As discussed, few studies of mortality risk have used biomarker measurements to capture exposure to passive smoking. That different cotinine measures have been deployed – urine, saliva, blood,^{10 12 33 34} – complicates synthesis, although correlations amongst the passive smoking indicators is high. Weak and modest associations have been reported for cotinine indices in relation to total mortality^{12 33 34} and lung cancer,³³ while associations between cotinine level and deaths from heart disease and cardiovascular disease vary.³³⁻³⁵ The shape of the cotinine-cardiovascular disease association in the current study suggests a threshold at low doses after which there is no distinct increase in mortality. This observation seems to accord with extant studies.^{12 33-35} The observed lower threshold in cancer mortality may indicate that low but detectable levels of cotinine are not carcinogenic. An explanation of the observed threshold for CVD and cancer mortality needs further investigation. By contrast, the relation between cotinine and cancers ascribed to passive smoking was incremental across the cotinine continuum.

Study strengths and limitations

A reliance on self-report of any characteristic may be problematic as interpretation may be hampered by socially desirable responses and smoking is no exception.^{36,37} Our study has the advantage of having biological measurement of passive smoking, salivary cotinine, which correlates highly with cotinine in blood²³ and may even offer higher sensitivity than cotinine from urine and serum,¹³ In addition, our study has an objective health outcome, i.e. cause of death was based on certification and coded according to the *International Classification of Diseases* (ICD, 10th revision).²⁶ However, while salivary cotinine may capture exposure in all contexts, it has a half-life of 20 h and will thus only index recent passive smoking. There is also some individual variability in nicotine metabolism and elimination.^{10,23,24} These conditions might have caused some misclassification of smokers and non-smokers. That salivary cotinine levels correlated strongly with self-reported active smoking status such that there was a marked difference between smokers and non-smokers (Figure 1) gives us confidence in our results for passive smoking.

There are some study limitations. Passive and active smoking were captured at a single point in time and this may have resulted in some degree of misclassification of the study participants who changed habits during follow-up – during the more than decade-long period of baseline data collection (1997 – 2008), smoking prevalence, and hence passive smoking, decreased considerably.³⁸ It is likely that this misclassification was not systematic with respect to the outcomes under study, and, as such, we have underestimated the health risks of passive smoking, possibly more for cancers due to a longer lag between exposure and outcome. Residual confounding is a perennial limitation in observational analyses and our study is no exception. Lastly, the use of cotinine, the most common biomarker of passive smoking, is not without its challenges. Other exposures that may influence cotinine level such as nicotine vapour from room surfaces, clothing and dust, some foods, smokeless tobacco products (snus) and nicotine

replacement therapy were not captured in the present study and were not taken into account.

However, we did exclude study members because their cotinine levels were too high for them to be realistically classified as non-smokers. It is possible that at least some of these people had used nicotine products other than cigarettes.

In conclusion, our study supports an association between objectively ascertained second-hand smoking and mortality from any death, cardiovascular disease and smoking-related cancers. The apparent threshold effects for some of these relationships require further exploration.

Data are available in a public, open access repository.³⁹

References

1. Office for National Statistics, UK. Adults smoking habits in the UK: 2018. Available at <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlife/expectancies/bulletins/adultsmokinghabitsingreatbritain/2018> [Accessed 22 January 2020]
2. World Health Organization: Tobacco. Fact sheet, 26 July 2019. Available at <https://www.who.int/news-room/fact-sheets/detail/tobacco> [Accessed 22 January 2020]
3. Haw SJ and Gruer L. Changes in the exposure of adult non-smokers to secondhand smoke after implementation of smoke-free legislation in Scotland: national sectional survey. *BMJ* 2007; 335: 549.
4. Jamrozik K. Estimate of deaths attributable to passive smoking among UK adults: database analysis. *BMJ* 2005; 330: p. 812.
5. Öberg M, Jaakola MS, Woodward A, *et al.* Worldwide burden of disease from exposure to second-hand smoke: a retrospective analyses of data from 192 countries. *The Lancet* 2011; 377:139-46.

6. Wartenberg D, Calle EE, Thun MJ, *et al.* Passive smoking exposure and female breast cancer mortality. *J Natl Cancer Inst* 2000;92:1666-73.
7. Eisner MD, Wang Y, Haight TJ, *et al.* Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. *Ann Epidemiol* 2007;17:364-73.
8. Cardenas VM, Thun MJ, Austin H, *et al.* Environmental tobacco smoke and lung cancer mortality in the American Cancer Society's Cancer Prevention Study. II. *Cancer Causes Control* 1997;8:57-64. Erratum in: *Cancer Causes Control* 1997;8:675.
9. Jiang J, Pang H, Liu B, *et al.* Effects of active, passive, and combined smoking on cervical cancer mortality: a nationwide proportional mortality study in Chinese urban women. *Cancer Causes Control* 2015;26:983-91.
10. Batty GD, Gale CR, Jefferis B, *et al.* Passive smoking assessed by salivary cotinine and self-report in relation to cause-specific mortality: 17-year follow-up of study participants in the UK Health and Lifestyle Survey. *J Epidemiol Community Health* 2014;68:1200-3.
11. Wulaningsih W, Serrano FE, Utarini A, *et al.*; PILAR Research Network. Smoking, second-hand smoke exposure and smoking cessation in relation to leukocyte telomere length and mortality. *Oncotarget* 2016;7:60419-31.
12. Lu L, Mackay DF, Pell JP. Secondhand smoke exposure and risk of incident peripheral arterial disease and mortality: a Scotland-wide retrospective cohort study of 4045 non-smokers with cotinine measurement. *BMC Public Health* 2018;18:348.
13. Gorber CS, Schofield-Hurwitz S, Hardt J, *et al.* The Accuracy of Self-reported smoking: A Systematic Review of the Relationship between Self-reported and Cotinine-assessed Smoking Status. *Nicotine Tob Res* 2009; 11: 12-24.
14. Gray L, Batty GD, Craig P, *et al.* Cohort profile: the Scottish health surveys cohort: linkage of study participants to routinely collected records for mortality, hospital discharge, cancer and offspring birth characteristics in three nationwide studies. *Int J Epidemiol* 2010; 39:345-50.

15. Mindell J, Biddulph JP, Hirani V, *et al.* Cohort profile: the health survey for England. *Int J Epidemiol* 2012; 41:1585-93.
16. Batty GD, Russ TC, Stamatakis E, *et al.* Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. *BMJ*. 2017; 356: j108.
17. Russ TC, Stamatakis E, Hamer M, *et al.* Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies. *BMJ*. 2012; 345: e4933.
18. Mestral dC, Bell S, Stamatakis E, *et al.* Testing differential associations between smoking and chronic disease across socioeconomic groups: pooled data from 15 prospective studies. *Epidemiology* 2019; 30: 48-51.
19. Feyerabend C, Russell MA. A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. *J Pharm Pharmacol* 1990; 42:450-2.
20. Bernert JT, Jacob P 3rd, Holiday DB, *et al.* Interlaboratory comparability of serum cotinine measurements at smoker and non-smoker concentration levels: a round-robin study. *Nicotine Tob Res* 2009;11:1458-66.
21. Craig R, Mindell J, Hirani V, eds. Leeds: NHS Information Centre; 2009. Health Survey for England 2008. Vol. 2 -- Methods and Documentation.
22. Scottish Health Survey 2012 - Volume 2 Technical Report. Available at <https://www.gov.scot/publications/scottish-health-survey-2012-volume-2-technical-report/pages/22/> [Accessed 21 November 2020]
23. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. *Epidemiol Rev*, 1996; **18**: p. 188-204.
24. Avila-Tang E, Al-Delaimi WK, Ashley DL, *et al.* Assessing secondhand smoke using biological markers. *Tobacco Control* 2013; 22: 164-71.

25. Office for National Statistics. National Statistics—Socioeconomic Classification Scheme. London, UK: Office for National Statistics, 2010. Available at <https://www.ons.gov.uk/methodology/classificationsandstandards/otherclassifications/thenationalstatistics socioeconomic classificationnssec basedonsoc2010> [Assessed 13 March 2020].
26. World Health Organization. International statistical classification of diseases and related health problems 10th revision Volume 2 Instruction manual Fifth edition 2016, ISBN 978 92 4 154916 5. Available at https://icd.who.int/browse10/Content/statichtml/ICD10Volume2_en_2016.pdf [Accessed 22 January 2020]
27. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Tobacco Smoke and Involuntary Smoking, Lyon, France 2004. Available at <https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Tobacco-Smoke-And-Involuntary-Smoking-2004> [Accessed 1 March 2020]
28. Batty GD, Kivimaki M, Gray L, *et al.* Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study, *Annals of Oncology* 2008; 19: 996–1002.
29. Whincup PH, Gilg JA, Emberson JR, *et al.* Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. *BMJ* 2004; 329: 200.
30. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, *et al.* Comparison of tests used to distinguish smokers from nonsmokers. *Am J Public Health* 1987; 77: 1435–8.
31. Cox DR. Regression models and life-tables. *J R Stat Soc [Ser B]* 1972; 34: 187–220.
32. Stata Press. Survival Analysis Reference Manual, ISBN-13: 978-1-59718-297-3, College Station, Texas 2019. Available at <http://www.stata.com/bookstore/survival-analysis-reference-manual/> [Accessed 22 January 2020].

33. Flores RM, Liu B, Taioli E. Association of serum cotinine levels and lung cancer mortality in non-smokers. *Carcinogenesis* 2016; 37: 1062–9.
34. Gallo V, Neasham D, Airoidi L, *et al.* Second-hand Smoke, Cotinine Levels, and Risk of Circulatory Mortality in a Large Cohort Study of Never-Smokers. *Epidemiology* 2010; 21: 207-14.
35. Rostron B. Mortality Risks Associated With Environmental Tobacco Smoke Exposure in the United States. *Nicotine Tob Res* 2013; 15: 1722–8.
36. Alamar B, Glantz SA. Effect of increased social unacceptability of cigarette smoking on reduction in cigarette consumption. *Am J Public Health* 2006; 96: 1359-63.
37. Fisher MA, Taylor GW, Shelton BJ, *et al.* Sociodemographic characteristics and diabetes predict invalid self-reported non-smoking in a population-based study of U.S. adults. *BMC Public Health*, 2007; 7: 33.
38. Office for National Statistics, UK. Smoking and drinking among adults 2009, in General Lifestyle Survey 2009, National Statistics: Newport, South Wales 2011. Available at https://sp.ukdataservice.ac.uk/doc/6716/mrdoc/pdf/2009_report.pdf [Accessed 22 January 2020]
39. UK Data Archive, University of Essex, UK. Available at: www.data-archive.ac.uk

Summary box:

What is already known on this subject?

- Passive smoking appears to be related to a range of chronic diseases
- With studies almost exclusively relying on self-reports of passive smoking, the magnitude of relationship may have been biased.
- There are also very few prospective cohort studies in this context, which, in the absence of clinical trials, provide the best evidence of a causal link.

What does this study add?

- In the present context, this multi-cohort study is the largest to date with data on a biomarker of passive smoking.
- In non-smokers, salivary cotinine above a threshold of 0.5 ng/ml was associated with a 20 to 40 % higher rate of death from all-causes, cardiovascular disease, and smoking-related cancers.

Figure legend:

Figure 1: Median salivary cotinine levels by self-reported smoking status. N=51 417

Figure 2: Deaths from any cause, cancer, cardiovascular disease (CVD) and smoking-related cancer by salivary cotinine level (ng/ml)

License for Publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in JECH and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

Competing interests: None declared.

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.